0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > IL-6 > IL6-H4218

Human IL-6 Protein, premium grade

GMP version GMP-L06H27 is now available for seamless transition.

Order Now

  • Synonym
    IL6,Interleukin-6,BSF2,HSF,IFNB2
  • Source
    Human IL-6, premium grade(IL6-H4218) is expressed from human 293 cells (HEK293). It contains AA Val 30 - Met 212 (Accession # NP_000591.1).
    Predicted N-terminus: Val 30
    Human IL-6, premium grade (IL6-H4218), designed for preclinical stage, has the same activity and performance with GMP Human IL-6 (GMP-L06H27), which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.
  • Molecular Characterization
    IL-6 Structure

    This protein carries no "tag".

    The protein has a calculated MW of 20.8 kDa. The protein migrates as 23-29 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.01 EU per μg by the LAL method.
  • Host Cell Protein
    <0.5 ng/µg of protein tested by ELISA.
  • Host Cell DNA
    <0.02 ng/μg of protein tested by qPCR.
  • Sterility
    Negative
  • Mycoplasma
    Negative.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
IL-6 SDS-PAGE

Human IL-6, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Bioactivity CELL BASE
 IL-6 CELL

Human IL-6, premium grade (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The specific activity of Human IL-6, premium grade is > 1.00×10^8 IU/mg, which is calibrated against human IL-6 WHO International Standard (NIBSC code: 21/308) (QC tested).

 IL-6 BATCH CELL BASE

Activity of three different production batches of Human IL-6 Protein, premium grade (Cat. No. IL6-H4218).

 IL-6 CELL

The activity of Human IL-6 Protein, premium grade (Cat. No. IL6-H4218) was higher than other competing products.

Bioactivity-Stability
 IL-6 STABILITY

The Cell based assay shows that Human IL-6 Protein, premium grade (Cat. No. IL6-H4218) is stable at 37°C for 48 hours.

 IL-6 STABILITY

The Cell based assay shows that Human IL-6 Protein, premium grade (Cat. No. IL6-H4218) is stable after freezing and thawing 3 times.

 IL-6 STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG IL-6.

  • Background
    Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €160.00

Price(EUR) : €290.00

Price(EUR) : €2130.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:6 Details
  • Number of Drugs in Clinical Trials:18 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message